Rhythm Pharmaceuticals Launches IMCIVREE in Japan After NHI Listing
IMCIVREE is approved in Japan for acquired hypothalamic obesity and is included on the NHI drug price list. It is the first approved therapy in Japan for the condition.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Rhythm Pharmaceuticals launches IMCIVREE in Japan for acquired hypothalamic obesity
Rhythm Pharmaceuticals launched IMCIVREE in Japan for acquired hypothalamic obesity following listing on the National Health Insurance drug price list. Market entry follows MHLW clearance in August, supported by Phase 3 TRANSCEND data showing an 18.8% placebo-adjusted BMI reduction. Rhythm estimates 5,000 to 8,000 peop
Rhythm launches IMCIVREE in Japan for acquired hypothalamic obesity
Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity.